International Stem Cell Corporation
International Stem Cell Corporation (ISCO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
isco · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
International Stem Cell CorporationYou ISCO | $1M | N/A | — | -$0.05 |
 Biocure Technology Inc. BICTF | $1M | N/A | — | -$0.01 |
 Biora Therapeutics, Inc. BIOR | $1M | N/A | — | -$78.69 |
 Biomind Labs Inc. BMNDF | $9M | N/A | — | -$0.01 |
 Chia Tai Enterprises International Limited CAIHF | $1M | 2.21x | -25.6% | $0.13 |
 DATATRAK International, Inc. DTRK | $0M | 3.70x | +24.5% | $0.10 |
 Evofem Biosciences, Inc. EVFM | $1M | 3.00x | +1.1% | $0.00 |
Industry Average 3 peers with valid PE | — | 2.97x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for International Stem Cell Corporation (ISCO) measures how much investors pay for each dollar of the company's trailing earnings. ISCO's current PE ratio of N/A is calculated by dividing its stock price of $0.17 by its TTM earnings per share of -$0.05.
Frequently asked questions
ISCO pe ratio · 6 questionsISCO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.17 and TTM EPS of -$0.05. Data sourced from Financial Modeling Prep via ISCO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · International Stem Cell Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09